The New New Leaf Ventures Ii Holding in Versartis, Inc
New Leaf Ventures Ii filed with the SEC SC 13D/A form for Versartis, Inc. The form can be accessed here: 000119312516767970. As reported in New Leaf Ventures Ii’s form, the filler as of late owns 5.9% or 2,039,223 shares of the Health Care–company.
Versartis, Inc stake is a new one for the and it was filed because of activity on November4, 2016. We feel this shows New Leaf Ventures Ii’s positive view for the stock.
Versartis, Inc Institutional Sentiment
Latest Security and Exchange filings show 60 investors own Versartis, Inc. The institutional ownership in Q3 2015 is high, at 60.73% of the outstanding shares. This is increased by 714558 the total institutional shares. 21135743 were the shares owned by these institutional investors. In total 10 funds opened new Versartis, Inc stakes, 27 increased stakes. There were 15 that closed positions and 14 reduced them.
3 managers had the stock in their top Ten. Notable investors are: New Leaf Venture Partners L.L.C., Aisling Capital Llc, Perceptive Advisors Llc..
Julian Baker And Felix Baker Baker Bros Advisors Lp is an institutional investor bullish on Versartis, Inc, owning 3241783 shares as of Q3 2015 for 0.35% of its portfolio. Joseph Edelman Perceptive Advisors Llc owns 2317954 shares or 2.14% of its portfolio. NY New Leaf Venture Partners Llc have 20.39% of their stock portfolio for 2039223 shares. Further, Aisling Capital Llc reported stake worth 4.62% of its US stock portfolio. The CA First Republic Investment Management Inc owns 48380 shares. Versartis, Inc is 0.01% of the manager’s US portfolio.
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Insitutional Activity: The institutional sentiment increased to 3 in Q2 2016. Its up 1.93, from 1.07 in 2016Q1. The ratio is positive, as 5 funds sold all Versartis Inc shares owned while 8 reduced positions. 5 funds bought stakes while 34 increased positions. They now own 20.36 million shares or 0.09% more from 20.34 million shares in 2016Q1.
Proshare Advisors Lc holds 0% or 25,250 shares in its portfolio. Kingdon Mngmt Limited Com owns 316,244 shares or 0.19% of their US portfolio. Goldman Sachs Grp accumulated 0% or 20,821 shares. California State Teachers Retirement last reported 0% of its portfolio in the stock. Northern Tru Corp has invested 0% of its portfolio in Versartis Inc (NASDAQ:VSAR). Bancorp Of Montreal Can owns 1,764 shares or 0% of their US portfolio. Teacher Retirement Sys Of Texas holds 0% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 2,564 shares. The United Kingdom-based Legal & General Gp Inc Public Limited Co has invested 0% in Versartis Inc (NASDAQ:VSAR). Parametric Assocs Lc accumulated 0% or 47,728 shares. Ubs Asset Mngmt Americas Inc has 0% invested in the company for 12,500 shares. Citigroup Incorporated last reported 10,956 shares in the company. Federated Investors Pa holds 0.03% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 1.08 million shares. Arrowpoint Asset Mgmt Ltd Company owns 241,603 shares or 0.05% of their US portfolio. National Bank & Trust Of Mellon Corp has 106,565 shares for 0% of their US portfolio. Jpmorgan Chase And Commerce has 856,524 shares for 0% of their US portfolio.
Insider Transactions: Since May 20, 2016, the stock had 1 insider purchase, and 5 insider sales for $6.88 million net activity. $15,392 worth of Versartis Inc (NASDAQ:VSAR) was sold by Brumm Joshua T on Wednesday, June 15. Shares for $7.00 million were bought by AKKARAJU SRINIVAS on Monday, October 3. Shares for $20,755 were sold by Varian John. Westberg Paul sold 725 shares worth $7,707. $70,093 worth of Versartis Inc (NASDAQ:VSAR) was sold by Shepard Jay.
The stock increased 1.19% or $0.15 during the last trading session, hitting $12.75. Versartis Inc (NASDAQ:VSAR) has risen 33.65% since April 13, 2016 and is uptrending. It has outperformed by 29.72% the S&P500.
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The company has a market cap of $469.75 million. The Firm is engaged in developing long-acting recombinant human growth hormone , somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. It currently has negative earnings. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Versartis Inc (NASDAQ:VSAR) Ratings Coverage
Out of 6 analysts covering Versartis Inc (NASDAQ:VSAR), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. $23 is the highest target while $17 is the lowest. The $20 average target is 56.86% above today’s ($12.75) stock price. Versartis Inc has been the topic of 8 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm has “Equal Weight” rating by Morgan Stanley given on Thursday, August 13. The stock has “Buy” rating given by Canaccord Genuity on Monday, September 21. The stock of Versartis Inc (NASDAQ:VSAR) has “Buy” rating given on Thursday, August 11 by Citigroup. The stock of Versartis Inc (NASDAQ:VSAR) has “Neutral” rating given on Thursday, August 20 by Credit Suisse. Credit Suisse downgraded Versartis Inc (NASDAQ:VSAR) on Thursday, December 17 to “Underperform” rating. As per Thursday, April 7, the company rating was initiated by Northland Capital. Piper Jaffray initiated the stock with “Overweight” rating in Tuesday, October 4 report.
More news for Versartis Inc (NASDAQ:VSAR) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on March 21, 2014. Quotes.Wsj.com‘s article titled: “Versartis Inc. VSAR (US: Nasdaq)” and published on March 21, 2014 is yet another important article.
According to Zacks Investment Research, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California.”
VSAR Company Profile
Versartis, Inc., incorporated on December 10, 2008, is an endocrine-focused biopharmaceutical company. The Firm is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.